EP4559485A3 - Formulation d'anticorps liquide - Google Patents

Formulation d'anticorps liquide

Info

Publication number
EP4559485A3
EP4559485A3 EP25155439.0A EP25155439A EP4559485A3 EP 4559485 A3 EP4559485 A3 EP 4559485A3 EP 25155439 A EP25155439 A EP 25155439A EP 4559485 A3 EP4559485 A3 EP 4559485A3
Authority
EP
European Patent Office
Prior art keywords
antibody formulation
liquid antibody
liquid
pharmaceutical formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP25155439.0A
Other languages
German (de)
English (en)
Other versions
EP4559485A2 (fr
Inventor
Sachin DUBEY
Paresh VADGAMA
Benoit STROBBE
Fillipa ABRANTES
Roberto Giovannini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ichnos Sciences SA
Original Assignee
Ichnos Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67297186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP4559485(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ichnos Sciences SA filed Critical Ichnos Sciences SA
Publication of EP4559485A2 publication Critical patent/EP4559485A2/fr
Publication of EP4559485A3 publication Critical patent/EP4559485A3/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2623—Ion-Exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/26—Further operations combined with membrane separation processes
    • B01D2311/2626—Absorption or adsorption
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Water Supply & Treatment (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
EP25155439.0A 2018-07-19 2019-07-19 Formulation d'anticorps liquide Pending EP4559485A3 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP18184533 2018-07-19
EP19156262 2019-02-08
PCT/EP2019/069522 WO2020016417A1 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide
EP19740024.5A EP3823594B1 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP19740024.5A Division EP3823594B1 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide

Publications (2)

Publication Number Publication Date
EP4559485A2 EP4559485A2 (fr) 2025-05-28
EP4559485A3 true EP4559485A3 (fr) 2025-08-06

Family

ID=67297186

Family Applications (3)

Application Number Title Priority Date Filing Date
EP19740024.5A Active EP3823594B1 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide
EP25155439.0A Pending EP4559485A3 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide
EP20703151.9A Withdrawn EP3999031A1 (fr) 2018-07-19 2020-01-22 Procédés pour obtenir une solution d'anticorps hautement concentrée

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP19740024.5A Active EP3823594B1 (fr) 2018-07-19 2019-07-19 Formulation d'anticorps liquide

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP20703151.9A Withdrawn EP3999031A1 (fr) 2018-07-19 2020-01-22 Procédés pour obtenir une solution d'anticorps hautement concentrée

Country Status (4)

Country Link
US (1) US20220251138A1 (fr)
EP (3) EP3823594B1 (fr)
ES (1) ES3014697T3 (fr)
WO (3) WO2020016417A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823594B1 (fr) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Formulation d'anticorps liquide
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
WO2021013689A1 (fr) * 2019-07-19 2021-01-28 Ichnos Sciences SA Formulation d'anticorps lyophilisée
WO2021171310A1 (fr) * 2020-02-24 2021-09-02 Indian Institute Of Technology Delhi Système de surveillance en temps réel d'une protéine et d'excipients
TW202323280A (zh) * 2021-10-15 2023-06-16 新加坡商創響私人有限公司 包含抗－ｏｘ４０單株抗體的藥物製劑
EP4252882A1 (fr) * 2022-03-31 2023-10-04 Sartorius Stedim Biotech GmbH Système de séparation et de purification d'un composant cible
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
IL326779A (en) * 2023-09-08 2026-04-01 Genentech Inc High viscosity ultrafiltration/diafiltration processes and single pass tangential flow filtration

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141239A1 (fr) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
WO2014207763A1 (fr) * 2013-06-25 2014-12-31 Cadila Healthcare Limited Procédé de purification pour anticorps monoclonaux
WO2015135884A1 (fr) * 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Purification d'immunoglobuline à l'aide d'étapes de pré-nettoyage
WO2016063299A2 (fr) * 2014-10-21 2016-04-28 Gennova Biopharmaceuticals Limited Nouveau procédé de purification pour l'isolement et la production commerciale de tnk-tpa recombinant (tenecteplase)
WO2017134292A1 (fr) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anticorps antagonistes anti-ox40 pour le traitement de dermatites atopiques

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
US20040191243A1 (en) 2002-12-13 2004-09-30 Bei Chen System and method for stabilizing antibodies with histidine
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20100136030A1 (en) 2007-02-27 2010-06-03 Lamhamedi-Cherradi Salah-Eddine Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases
AU2014203661A1 (en) 2007-06-14 2014-07-24 Biogen Ma Inc. Antibody Formulations
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BRPI1008692B8 (pt) 2009-02-17 2021-05-25 Ucb Biopharma Sprl anticorpo antagonista tendo especificidade para ox40 humano, sequência de dna isolado, vetor de clonagem ou de expressão, célula hospedeira, processo para a produção do referido anticorpo, composição farmacêutica, uso do 5 referido anticorpo e proteína de fusão
EP2399604A1 (fr) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Nouvelle formulation d'anticorps
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
AU2015310879A1 (en) 2014-09-03 2017-03-02 Medimmune Limited Stable anti-IL-4R-alpha antibody formulation
FR3025515B1 (fr) * 2014-09-05 2016-09-09 Lab Francais Du Fractionnement Procede de purification d'un anticorps monoclonal
EP3383914A4 (fr) 2015-12-02 2019-10-30 Agenus Inc. Anticorps anti-ox40 et leurs procédés d'utilisation
MA44763A (fr) 2016-04-28 2019-03-06 Biogen Ma Inc Compositions pharmaceutiques et régimes posologiques destinés à une utilisation clinique d'anticorps anti-antigène 2 de cellules dendritiques du sang
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
WO2019229155A1 (fr) 2018-05-31 2019-12-05 Glenmark Pharmceuticals S.A. Anticorps antagonistes anti-ox40 et dosage pour le traitement de troubles à médiation par ox40
EP3823594B1 (fr) 2018-07-19 2025-02-05 Ichnos Sciences S.A. Formulation d'anticorps liquide

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009141239A1 (fr) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag Formulation pharmaceutique comprenant un anticorps contre ox40l, utilisations de celle-ci
WO2014207763A1 (fr) * 2013-06-25 2014-12-31 Cadila Healthcare Limited Procédé de purification pour anticorps monoclonaux
WO2015135884A1 (fr) * 2014-03-10 2015-09-17 Richter Gedeon Nyrt. Purification d'immunoglobuline à l'aide d'étapes de pré-nettoyage
WO2016063299A2 (fr) * 2014-10-21 2016-04-28 Gennova Biopharmaceuticals Limited Nouveau procédé de purification pour l'isolement et la production commerciale de tnk-tpa recombinant (tenecteplase)
WO2017134292A1 (fr) * 2016-02-04 2017-08-10 Glenmark Pharmaceuticals S.A. Anticorps antagonistes anti-ox40 pour le traitement de dermatites atopiques

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
W BPS BIOSCIENCE ET AL: "Data Sheet Antagonist Antibody Anti-Ox40", CANCER IMMUNOLOGY IMMUNOLOGY & CELL BIOLOGY, 17 May 2018 (2018-05-17), pages 1 - 1, XP055620649, Retrieved from the Internet <URL:http://bpsbioscience.com/media/wysiwyg/72063-1_Lot_161005_1.pdf> [retrieved on 20190910] *

Also Published As

Publication number Publication date
EP3823594B1 (fr) 2025-02-05
EP3823594A1 (fr) 2021-05-26
WO2020016417A1 (fr) 2020-01-23
ES3014697T3 (en) 2025-04-24
EP3999031A1 (fr) 2022-05-25
WO2021013372A1 (fr) 2021-01-28
WO2021013385A1 (fr) 2021-01-28
US20220251138A1 (en) 2022-08-11
EP4559485A2 (fr) 2025-05-28

Similar Documents

Publication Publication Date Title
WO2021021837A3 (fr) Formulations d&#39;anticorps anti-pvrig et leurs utilisations
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
EP4285928A3 (fr) Formulations d&#39;anticorps anti-pdl1
PH12018500894A1 (en) Aqueous pharmaceutical formulation comprising anti-pd-l1 antibody avelumab
WO2019171253A8 (fr) Compositions d&#39;anticorps anti-pd -1
MX2017009759A (es) Formulacion de anticuerpo del anti-factor de crecimiento endotelial vascular (vegf) acuosa estable.
EP4335874A3 (fr) Anticorps anti-hla-g et leur utilisation
WO2020127377A9 (fr) Molécule bifonctionnelle anti-pd-1/il -7
MX2017004975A (es) Composiciones de anticuerpos anti-il-7r.
EP4438060A3 (fr) Formulations d&#39;anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes
MX2017010400A (es) Formulacion liquida estable para anticuerpos monoclonales.
EP3773694A4 (fr) Formulation d&#39;anticorps
TWD204242S (zh) Ｇｐｓ裝置
AR098168A1 (es) Formulación estable de insulina glulisina
PH12021552150A1 (en) Anti-il36r antibody formulations
EP3773696A4 (fr) Formulations stables d&#39;anticorps thérapeutique
EP4487829A3 (fr) Applicateur de liquide pour l&#39;administration de vaccins
PH12019502075A1 (en) A liquid formulation of anti-tnf alpha antibody
MX2019010367A (es) Formulacion acuosa de anticuerpo anti ligando 1 de muerte programada (pd-l1).
WO2021118930A3 (fr) Formulations d&#39;anticorps anti-pd-l1
TWD192262S (zh) Infusion Pump
MX2019010330A (es) Formulaciones con mejora de la estabilidad.
EP4520347A3 (fr) Composition pharmaceutique
EP3773695A4 (fr) Formulation d&#39;anticorps stable
EP3958903A4 (fr) Formulation d&#39;anticorps

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN PUBLISHED

AC Divisional application: reference to earlier application

Ref document number: 3823594

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0047360000

Ipc: A61K0009080000

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 9/08 20060101AFI20250702BHEP

Ipc: A61K 39/00 20060101ALI20250702BHEP

Ipc: A61K 9/00 20060101ALI20250702BHEP

Ipc: A61K 47/18 20170101ALI20250702BHEP

Ipc: A61K 47/36 20060101ALI20250702BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS